-
Je něco špatně v tomto záznamu ?
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
HP. Erba, P. Montesinos, HJ. Kim, E. Patkowska, R. Vrhovac, P. Žák, PN. Wang, T. Mitov, J. Hanyok, YM. Kamel, JEC. Rohrbach, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, AE. Perl, MA. Sekeres, H. Dombret, S. Amadori, J. Wang, MJ. Levis, RF....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu randomizované kontrolované studie, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
- MeSH
- akutní myeloidní leukemie * farmakoterapie genetika MeSH
- benzothiazoly * terapeutické užití MeSH
- cytarabin MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- fenylmočovinové sloučeniny * terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- senioři MeSH
- tyrosinkinasa 3 podobná fms antagonisté a inhibitory genetika MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML. The aim of the study was to compare the effect of quizartinib versus placebo on overall survival in patients with FLT3-ITD-positive newly diagnosed AML aged 18-75 years. METHODS: We conducted a randomised, double-blind, placebo-controlled, phase 3 trial comparing quizartinib and placebo in combination with chemotherapy in induction and consolidation, followed by quizartinib or placebo single-agent continuation, in patients with FLT3-ITD-positive newly diagnosed AML at 193 hospitals and clinics in 26 countries in Europe; North America; and Asia, Australia, and South America. Patients aged 18-75 years were eligible. Patients were randomly assigned (1:1) to the quizartinib group or the placebo group by an independent biostatistician through an interactive web and voice response system, stratified by region, age, and white blood cell count at diagnosis. Patients, investigators, funders, and contract research organisations were masked to treatments assigned. Induction therapy comprised a standard 7 + 3 induction regimen of cytarabine 100 mg/m2 per day (or 200 mg/m2 per day allowed if institutional or local standard) by continuous intravenous infusion from day 1 to day 7 and anthracycline (daunorubicin 60 mg/m2 per day or idarubicin 12 mg/m2 per day) by intravenous infusion on days 1, 2, and 3, then quizartinib 40 mg orally or placebo once per day, starting on day 8, for 14 days. Patients with complete remission or complete remission with incomplete neutrophil or platelet recovery received standard consolidation with high-dose cytarabine plus quizartinib (40 mg per day orally) or placebo, allogeneic haematopoietic cell transplantation (allo-HCT), or both as consolidation therapy, followed by continuation of single-agent quizartinib or placebo for up to 3 years. The primary outcome was overall survival, defined as time from randomisation until death from any cause and assessed in the intention-to-treat population. Safety was evaluated in all patients who received at least one dose of quizartinib or placebo. This study is registered with ClinicalTrials.gov (NCT02668653). FINDINGS: Between Sept 27, 2016, and Aug 14, 2019, 3468 patients with AML were screened and 539 patients (294 [55%] male patients and 245 [45%] female patients) with FLT3-ITD-positive AML were included and randomly assigned to the quizartinib group (n=268) or placebo group (n=271). 148 (55%) of 268 patients in the quizartinib group and 168 (62%) of 271 patients in the placebo group discontinued the study, primarily because of death (133 [90%] of 148 in the quizartinib group vs 158 [94%] of 168 in the placebo group) or withdrawal of consent (13 [9%] of 148 in the quizartinib group vs 9 [5%] of 168 in the placebo group). Median age was 56 years (range 20-75, IQR 46·0-65·0). At a median follow-up of 39·2 months (IQR 31·9-45·8), median overall survival was 31·9 months (95% CI 21·0-not estimable) for quizartinib versus 15·1 months (13·2-26·2) for placebo (hazard ratio 0·78, 95% CI 0·62-0·98, p=0·032). Similar proportions of patients in the quizartinib and placebo groups had at least one adverse event (264 [100%] of 265 in the quizartinib group and 265 [99%] of 268 in the placebo group) and one grade 3 or higher adverse event (244 [92%] of 265 in the quizartinib group and 240 [90%] of 268 in the placebo group). The most common grade 3 or 4 adverse events were febrile neutropenia, hypokalaemia, and pneumonia in both groups and neutropenia in the quizartinib group. INTERPRETATION: The addition of quizartinib to standard chemotherapy with or without allo-HCT, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival in adults aged 18-75 years with FLT3-ITD-positive newly diagnosed AML. Based on the results from the QuANTUM-First trial, quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML. FUNDING: Daiichi Sankyo.
Augusta University Medical Center Augusta University Augusta GA USA
Chang Gung Medical Foundation Linkou Taiwan
Daiichi Sankyo Basking Ridge NJ USA
Division of Hematologic Malignancies Johns Hopkins University Baltimore MD USA
Division of Hematology Oncology University of Pennsylvania Philadelphia PA USA
Duke Cancer Institute Durham NC USA
Hematology Department La Fe University and Polytechnic Hospital Valencia Spain
Institute of Hematology and Blood Diseases Hospital Tianjin China
Institute of Hematology and Blood Transfusion Warsaw Poland
Saint Louis Hospital University of Paris Paris France
Sylvester Cancer Center University of Miami Health System Miami FL USA
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011440
- 003
- CZ-PrNML
- 005
- 20240418103221.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(23)00464-6 $2 doi
- 035 __
- $a (PubMed)37116523
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Erba, Harry P $u Duke Cancer Institute, Durham, NC, USA. Electronic address: harry.erba@duke.edu
- 245 10
- $a Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial / $c HP. Erba, P. Montesinos, HJ. Kim, E. Patkowska, R. Vrhovac, P. Žák, PN. Wang, T. Mitov, J. Hanyok, YM. Kamel, JEC. Rohrbach, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, AE. Perl, MA. Sekeres, H. Dombret, S. Amadori, J. Wang, MJ. Levis, RF. Schlenk, QuANTUM-First Study Group
- 520 9_
- $a BACKGROUND: Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML. The aim of the study was to compare the effect of quizartinib versus placebo on overall survival in patients with FLT3-ITD-positive newly diagnosed AML aged 18-75 years. METHODS: We conducted a randomised, double-blind, placebo-controlled, phase 3 trial comparing quizartinib and placebo in combination with chemotherapy in induction and consolidation, followed by quizartinib or placebo single-agent continuation, in patients with FLT3-ITD-positive newly diagnosed AML at 193 hospitals and clinics in 26 countries in Europe; North America; and Asia, Australia, and South America. Patients aged 18-75 years were eligible. Patients were randomly assigned (1:1) to the quizartinib group or the placebo group by an independent biostatistician through an interactive web and voice response system, stratified by region, age, and white blood cell count at diagnosis. Patients, investigators, funders, and contract research organisations were masked to treatments assigned. Induction therapy comprised a standard 7 + 3 induction regimen of cytarabine 100 mg/m2 per day (or 200 mg/m2 per day allowed if institutional or local standard) by continuous intravenous infusion from day 1 to day 7 and anthracycline (daunorubicin 60 mg/m2 per day or idarubicin 12 mg/m2 per day) by intravenous infusion on days 1, 2, and 3, then quizartinib 40 mg orally or placebo once per day, starting on day 8, for 14 days. Patients with complete remission or complete remission with incomplete neutrophil or platelet recovery received standard consolidation with high-dose cytarabine plus quizartinib (40 mg per day orally) or placebo, allogeneic haematopoietic cell transplantation (allo-HCT), or both as consolidation therapy, followed by continuation of single-agent quizartinib or placebo for up to 3 years. The primary outcome was overall survival, defined as time from randomisation until death from any cause and assessed in the intention-to-treat population. Safety was evaluated in all patients who received at least one dose of quizartinib or placebo. This study is registered with ClinicalTrials.gov (NCT02668653). FINDINGS: Between Sept 27, 2016, and Aug 14, 2019, 3468 patients with AML were screened and 539 patients (294 [55%] male patients and 245 [45%] female patients) with FLT3-ITD-positive AML were included and randomly assigned to the quizartinib group (n=268) or placebo group (n=271). 148 (55%) of 268 patients in the quizartinib group and 168 (62%) of 271 patients in the placebo group discontinued the study, primarily because of death (133 [90%] of 148 in the quizartinib group vs 158 [94%] of 168 in the placebo group) or withdrawal of consent (13 [9%] of 148 in the quizartinib group vs 9 [5%] of 168 in the placebo group). Median age was 56 years (range 20-75, IQR 46·0-65·0). At a median follow-up of 39·2 months (IQR 31·9-45·8), median overall survival was 31·9 months (95% CI 21·0-not estimable) for quizartinib versus 15·1 months (13·2-26·2) for placebo (hazard ratio 0·78, 95% CI 0·62-0·98, p=0·032). Similar proportions of patients in the quizartinib and placebo groups had at least one adverse event (264 [100%] of 265 in the quizartinib group and 265 [99%] of 268 in the placebo group) and one grade 3 or higher adverse event (244 [92%] of 265 in the quizartinib group and 240 [90%] of 268 in the placebo group). The most common grade 3 or 4 adverse events were febrile neutropenia, hypokalaemia, and pneumonia in both groups and neutropenia in the quizartinib group. INTERPRETATION: The addition of quizartinib to standard chemotherapy with or without allo-HCT, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival in adults aged 18-75 years with FLT3-ITD-positive newly diagnosed AML. Based on the results from the QuANTUM-First trial, quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML. FUNDING: Daiichi Sankyo.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 12
- $a benzothiazoly $x terapeutické užití $7 D052160
- 650 _2
- $a cytarabin $7 D003561
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a tyrosinkinasa 3 podobná fms $x antagonisté a inhibitory $x genetika $7 D051941
- 650 12
- $a akutní myeloidní leukemie $x farmakoterapie $x genetika $7 D015470
- 650 12
- $a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Montesinos, Pau $u Hematology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
- 700 1_
- $a Kim, Hee-Je $u Department of Hematology, Catholic Hematology Hospital, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- 700 1_
- $a Patkowska, Elżbieta $u Institute of Hematology and Blood Transfusion, Warsaw, Poland
- 700 1_
- $a Vrhovac, Radovan $u Division of Hematology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia
- 700 1_
- $a Žák, Pavel $u Department of Internal Medicine-Haematology, University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Wang, Po-Nan $u Chang Gung Medical Foundation, Linkou, Taiwan
- 700 1_
- $a Mitov, Tsvetomir $u Daiichi Sankyo UK, London, UK
- 700 1_
- $a Hanyok, James $u Daiichi Sankyo, Basking Ridge, NJ, USA
- 700 1_
- $a Kamel, Yasser Mostafa $u Daiichi Sankyo, Basking Ridge, NJ, USA
- 700 1_
- $a Rohrbach, Jaime E Connolly $u Daiichi Sankyo, Basking Ridge, NJ, USA
- 700 1_
- $a Liu, Li $u Daiichi Sankyo, Basking Ridge, NJ, USA
- 700 1_
- $a Benzohra, Aziz $u Daiichi Sankyo, Basking Ridge, NJ, USA
- 700 1_
- $a Lesegretain, Arnaud $u Daiichi Sankyo, Basking Ridge, NJ, USA
- 700 1_
- $a Cortes, Jorge $u Augusta University Medical Center, Augusta University, Augusta, GA, USA
- 700 1_
- $a Perl, Alexander E $u Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA
- 700 1_
- $a Sekeres, Mikkael A $u Sylvester Cancer Center, University of Miami Health System, Miami, FL, USA
- 700 1_
- $a Dombret, Hervé $u Saint Louis Hospital, University of Paris, Paris, France $7 xx0316388
- 700 1_
- $a Amadori, Sergio $u Tor Vergata Polyclinic Hospital Rome, Rome, Italy
- 700 1_
- $a Wang, Jianxiang $u Institute of Hematology and Blood Diseases Hospital, Tianjin, China
- 700 1_
- $a Levis, Mark J $u Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA
- 700 1_
- $a Schlenk, Richard F $u National Center of Tumor Diseases Trial Center, German Cancer Research Center, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- 710 2_
- $a QuANTUM-First Study Group
- 773 0_
- $w MED00010161 $t Lancet $x 1474-547X $g Roč. 401, č. 10388 (2023), s. 1571-1583
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37116523 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20240418103215 $b ABA008
- 999 __
- $a ok $b bmc $g 1963697 $s 1197705
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 401 $c 10388 $d 1571-1583 $e 20230425 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20230718